Abstract
Aztreonam (30 mg/kg) was administered intravenously every 12 h during week 1 and every 8 h during weeks 2 to 4 of life to 26 low-birth-weight (less than 2,000 g) infants, and plasma concentration-time curves were measured on two occasions. The pharmacokinetics were described equally well by one-compartment and noncompartment models, and the values on day 1 were similar to those measured during the steady state on days 3 to 6. The mean peak plasma concentrations at completion of the 10-min infusion were from 65 to 83 micrograms/ml, the higher concentrations being seen in the larger infants. The half-lives of aztreonam ranged from 5.4 to 8.6 h and did not change significantly with birth weight. The median peak and trough plasma bactericidal titer against a strain of Escherichia coli (MBC, 10 micrograms/ml) was 1:16. Against a strain of Pseudomonas aeruginosa (MBC, 16 micrograms/ml), the median peak and trough bactericidal titers were 1:8 to 1:16 and 1:4, respectively. The urinary concentrations of aztreonam on day 1 of therapy were from 24 to 460.7 micrograms/ml (mean +/- 1 standard deviation, 254 +/- 113 micrograms/ml).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fainstein V., Weaver S., Bodey G. P. Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother. 1982 Feb;21(2):294–298. doi: 10.1128/aac.21.2.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Marymont J. H., Jr, Wentz R. M. Serial dilution antibiotic sensitivity testing with the microtitrator system. Am J Clin Pathol. 1966 May;45(5):548–551. doi: 10.1093/ajcp/45.5.548. [DOI] [PubMed] [Google Scholar]
- McCracken G. H., Jr, Sakata Y., Olsen K. D. Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1. Antimicrob Agents Chemother. 1985 Apr;27(4):655–656. doi: 10.1128/aac.27.4.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mihindu J. C., Scheld W. M., Bolton N. D., Spyker D. A., Swabb E. A., Bolton W. K. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1983 Aug;24(2):252–261. doi: 10.1128/aac.24.2.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Scheld W. M., Brodeur J. P., Gratz J. C., Foresman P., Rodeheaver G. Evaluation of aztreonam in experimental bacterial meningitis and cerebritis. Antimicrob Agents Chemother. 1983 Nov;24(5):682–688. doi: 10.1128/aac.24.5.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simon H. J., Yin E. J. Microbioassay of antimicrobial agents. Appl Microbiol. 1970 Apr;19(4):573–579. doi: 10.1128/am.19.4.573-579.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stutman H. R., Marks M. I., Swabb E. A. Single-dose pharmacokinetics of aztreonam in pediatric patients. Antimicrob Agents Chemother. 1984 Aug;26(2):196–199. doi: 10.1128/aac.26.2.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swabb E. A., Sugerman A. A., Platt T. B., Pilkiewicz F. G., Frantz M. Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother. 1982 Jun;21(6):944–949. doi: 10.1128/aac.21.6.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sykes R. B., Bonner D. P., Bush K., Georgopapadakou N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):85–92. doi: 10.1128/aac.21.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]